Combining options in metastatic prostate cancer

Research output: Contribution to journalComment/debate

Abstract

Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

Original languageEnglish (US)
JournalNature Reviews Urology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Prostatic Neoplasms
docetaxel
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Combining options in metastatic prostate cancer. / Kopp, Ryan; Beer, Tomasz (Tom).

In: Nature Reviews Urology, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{9bfd93261ace48bfa1c1886014406b08,
title = "Combining options in metastatic prostate cancer",
abstract = "Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.",
author = "Ryan Kopp and Beer, {Tomasz (Tom)}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41585-019-0217-z",
language = "English (US)",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Combining options in metastatic prostate cancer

AU - Kopp, Ryan

AU - Beer, Tomasz (Tom)

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

AB - Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

UR - http://www.scopus.com/inward/record.url?scp=85069468976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069468976&partnerID=8YFLogxK

U2 - 10.1038/s41585-019-0217-z

DO - 10.1038/s41585-019-0217-z

M3 - Comment/debate

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

ER -